PharmaTimes World News

Biogen files fampridine PR in Europe, teams up with Trillium

Wed, 01/12/2010 - 01:00

Biogen Idec is asking regulators in Europe to approve a prolonged-release version of fampridine to improve walking in multiple sclerosis patients. It also noted that Tysabri sales have topped the $1 billion mark

US govt study probes “extraordinary” Rx price rises

Wed, 01/12/2010 - 01:00

Limited competition and a lack of therapeutically-equivalent drugs may be contributing to “extraordinary price rises” for branded medicines, a US government report claimed yesterday.

Alcon shareholders file lawsuit to stop 'brazen' Novartis takeover

Wed, 01/12/2010 - 01:00

A class action lawsuit has been filed in the USA on behalf of minority shareholders in Alcon who are trying to throw a spanner in the works of Novartis’ $39.1 billion takeover of the eye care specialist

FDA panel rejects expansion of Forest drug

Wed, 01/12/2010 - 01:00

Advisors to the US Food and Drug Administration have unanimously rejected Forest Laboratories attempt to market its antihypertensive Bystolic for the treatment of chronic heart failure

New year, new inflammatory bowel disease candidate for GSK

Wed, 01/12/2010 - 01:00

UK drug giant GlaxoSmithKline has kicked off the New Year by signing up for development and commercialisation rights to US group ChemoCentryx’ inflammatory bowel disease candidate Traficet-EN.

Galapagos signs major COPD deal with Roche

Mon, 01/11/2010 - 01:00

Shares in Galapagos are on the rise after the Belgian company signed an agreement with Roche which could be worth as much as 400 million euros

USA needs more time to review MannKind’s inhaled insulin

Mon, 01/11/2010 - 01:00

After a week of breathless predictions from industry observers, MannKind Corp has revealed that a US regulatory review of its inhaled insulin therapy Afrezza is going to take a bit longer

Hong Kong urged to tighten drug safety controls

Mon, 01/11/2010 - 01:00

Hong Kong’s Legislative Council Panel on Health Services will today consider recommendations aimed at improving the safety of the drug supply, including the establishment of a dedicated Centre for Drug Safety.